This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

The Clinical Trials Industry’s Weekly Update: News, Analysis and Insider Insights Delivered Straight To Your Inbox

Deep Lens launches tech to help cancer drug developers focus on recruitment

Share this article

Deep Lens has launched an AI-based platform designed to help sponsors identify the best study sites for cancer drug clinical trials.

The “Real Time Feasibility” platform uses software developed by Deep Lens to analyze a network of community oncology sites and integrated workflows that combine EMR, lab and genomic data to gain real-time insight about specific patient populations.

Columbus, Ohio-based Deep Lens said the idea is to help sponsors and CROs accelerate recruitment explaining that, unlike traditional feasibility studies rely on physicians estimating enrolment based on the number of patients, the AI approach has potential to be more accurate.

Company president Simon Arkell said, "This new dashboard-based subscription offering provides any oncology-focused biopharma company or CRO the ability to quickly and easily view real-time patient counts across our fast-growing network to assess a study’s fit with any study.”

He added, “The use of AI enables scalable data analysis, and any new partner can be set up with real-time insights across our entire network in a matter of hours.”

Deep Lens also revealed that Bethesda, Maryland-based CRO Precision for Medicine would deploy the solution to assist its sponsors in rapidly identifying the sites and patients best suited for their oncology studies.

Megan Liles, Vice President, Clinical Solutions at the CRO, said “Even with tremendous advances in our knowledge of diagnosing and treating cancer – precision oncology trials may struggle to find and enroll enough patients to progress to the next stage of development.

“Our vision is to streamline the clinical trial recruitment process for sponsors by giving them real-time, consistently updated patient insights so they can enroll trials faster and with more accuracy.”


Anything that accelerated patient recruitment is likely to be welcomed by cancer drug developers.

According to recent analysis published in the Journal of The American Medical Association (JAMA) it costs approximately $1 million per day to bring a cancer drug to market.

The launch comes just a few months after Deep Lens granted the Pacific Cancer Care the right to use its artificial intelligence technology to screen patients and automatically and match them to recruiting studies.

Image: Stock Photo Secrets

Share this article

Sign up for Clinical Insider email updates